Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators

Recent Progress in Hormone Research

Volumn 57, Issue , 2002, Pages 295-316

  McDonnell, Donald P ^a   Connor, Caroline E ^a   Wijayaratne, Ashini ^a   Chang, Ching Yi ^a   Norris, John D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; DRUG MECHANISM; DRUG RECEPTOR BINDING; OSTEOPOROSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SURFACE PROPERTY;

ANIMALS; DRUG RESISTANCE; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; PROTEIN CONFORMATION; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 0036375102     PISSN: 00799963     EISSN: None     Source Type: Journal    
DOI: 10.1210/rp.57.1.295     Document Type: Article

References (83)

1. Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription
2. Clomiphene protects against osteoporosis in the mature ovariectomized rat
3. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain
4. Tamoxifen withdrawal response. Report of a case
5. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
6. Molecular basis of agonism and antagonism in the oestrogen receptor
7. Clinical significance of tamoxifen withdrawal response
8. Actions of ovarian steroid hormones
9. Female sex steroids: Receptors and function
10. Effects of a new anti-estrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin secretion
11. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor
12. Estrogen receptor null mice: What have we learned and where will they lead us?
13. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
14. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
15. Tamoxifen for early breast cancer: An overview of the randomised trials
16. Reduction of vertebral risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators
17. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
18. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial
19. Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: A southeastern cancer study group trial
20. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
21. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
22. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
23. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats
24. Regulation of metallothionein II messenger ribonucleic acid measures exogenous estrogen receptor-β activity in SAOS-2 and LNCaPLN3 cells
25. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
26. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors
27. Response to a specific antiestrogen (ICI182,780) in tamoxifen-resistant breast cancer
28. Circumvention of tamoxifen resistance by the pure antiestrogen ICI 182,780
29. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element
30. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol
31. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium
32. Effects of tamoxifen on uterus
33. Combinatorial roles of the nuclear receptor corepressor in transcription and development
34. Estrogen receptor mutations in tamoxifen-resistant breast cancer
35. From peptides to drugs via phage display
36. Effects of CP-336, 156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models
37. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-α and estrogen receptor-β: Correlations with biological character and distinct differences among SRC coactivator family members
38. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
39. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β
40. Clomiphene and tamoxifen action in the rat uterus
41. Tamoxifen-induced tumor stumulation and withdrawal response
42. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
43. The molecular pharmacology of SERMs
44. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
45. Transcription activation by the human estrogen receptor subtype β (ERβ) studied with ERβ and ERα receptor chimeras
46. Nuclear receptor coregulators: Cellular and molecular biology
47. An issue of tissues: Divining the split personalities of selective estrogen receptor modulators
48. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor
49. ERβ: Identification and characterization of a novel human estrogen receptor
50. Other selective oestrogen receptor modulators (SERMs) in development
51. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity
52. Enhancement of estrogen receptor transcriptionl activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology
53. Peptide antagonists of the human estrogen receptor
54. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
55. Tamoxifen in the treatment of breast cancer
56. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
57. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients
58. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
59. Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ
60. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
61. Structural insights into the mode of action of a pure antiestrogen
62. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen and ICI164,384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells
63. Dopamine activation of an orphan of the steroid receptor superfamily
64. Dopaminergic and ligand-independent activation of steroid hormone receptors
65. Phosphorylation of steroid receptor coactivator-1: Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway
66. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
67. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
68. The distribution of estrogen receptor-β mRNA in the rat hypothalamus
69. Role of estrogen receptor variants in the development of hormone resistance in breast cancer
70. Coactivator and corepressor regulation of the agonist/ antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
71. Cloning of ligand targets: Systematic isolation of SH3 domain-containing proteins
72. Steroid receptor coactivator-1 is a histone acetyltransferase
73. Response of metastatic breast cancer to tamoxifen withdrawal: Report of a case
74. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer
75. Tamoxifen resistance in breast cancer
76. Raloxifene preserves bone strength and bone mass in ovariectomized rats
77. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats
78. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
79. Comparative analyses of the mechanistic differences among antiestrogens
80. 3-[4-(1,2-diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats
81. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of ER in bone
82. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
83. Hormone replacement and cardiovascular risk factors